Effect of Combined Intravenous Glucocorticoids and Orbital Radiotherapy in Restoring Driving Competency in Patients with Graves’ Orbitopathy

Abstract

Intravenous glucocorticoids and orbital radiotherapy are effective treatments for moderate-to-severe and active Graves’ orbitopathy. We examined the ophthalmological outcome in daily life activities, such as driving competency. In a retrospective case series, 23 patients with moderate-to-severe and active Graves’ disease (14 women and 7 men) were consecutively treated with combined orbital radiotherapy (13 Gy) and intravenous methylprednisolone (500 mg weekly for 6 consecutive weeks and 250 mg weekly for consecutive 6 weeks). The pretreatment Clinical Activity Score of 5.2 points (SD±0.9) decreased significantly to 2.7 points (SD±1.1) in the 12-month follow-up. Inflammatory eye signs, for example, pain and pressure sensation, caruncle inflammation, eyelid swelling, and exophthalmos decreased significantly. However, there was no significant improvement of eye motility. Despite anti-inflammatory treatment, 13 patients (61.9%) were not fit to drive a car under binocular conditions and additional stabismologic therapy including strabismus surgery was required. The combined therapy of intravenous glucocorticoids and orbital radiotherapy reduced inflammatory ophthalmological signs. In most cases strabismologic intervention including eye muscle surgery was necessary to restore driving competency.

Graves’ disease - treatment of moderate-to-severe Graves’ disease - driving competency

References

• 1 Ludgate M, Baker G. Inducing Graves’ ophthalmopathy.  J Endocrinol Invest. 2004;  27 211-215
• 2 Bahn RS. TSH receptor expression in orbital disease and its role in the pathogenesis of Graves’ ophthalmopathy.  J Endocrinol Invest. 2004;  27 216-220
• 3 Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy.  J Endocrinol Invest. 2004;  27 237-245
• 4 Gerding MN, Terwee CB, Dekker FW, Kornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.  Thyroid. 1997;  7 885-889
• 5 Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives.  Endocr Rev. 2000;  21 168-199
• 6 Marcocci C, Marino M, Rocchi R, Menconi F, Morabito E, Pinchera A. Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy.  J Endocrinol Invest. 2004;  27 272-280
• 7 Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri A, Andreani D, Cavallacci G, Baschieri L, Pinchera A. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone.  J Clin Endocrinol Metab. 1983;  56 1139-1144
• 8 Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high-dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study.  J Endocrinol Invest. 1991;  14 853-860
• 9 Perros P, Dickinson AJ. Ophthalmopathy. In: Braverman LE, Utiger RD, eds. Werner's and Ingbar's The Thyroid – A fundamental and Clinical Text. Philadelphia: Lippincott Williams and Wilkins 2005: 474-478
• 10 Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A. Comparison of the effectiveness and tolerability of intravenous and oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study.  J Clin Endocrinol Metab. 2001;  86 3562-3567
• 11 Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G. High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy.  J Endocr Invest. 2001;  24 152-158
• 12 Kauppinen-Makelin R, Karmi A, Leinonen B, Loyttyniemi E, Salonen O, Sane T, Sctala K, Viikari I, Heufelde A, Valimaki M. High dose intravenous methylprednisolone pulse therapy versus oral prednisolone for thyroid-associated ophthalmopathy.  Acta Ophthalmol Scand. 2002;  80 316-321
• 13 Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy.  J Clin Endocrinol Metab. 2005;  90 5234-5240
• 14 Ng CM, Yuen HK, Chol KL, Chan MK, Yuen KT, Ng YW, Tui SC. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study.  Hong Kong Med J. 2005;  11 322-330
• 15 Wiersinga WM, Prummel MF. Graves’ ophthalmopathy: a rational approach to treatment.  Trends Endocrinol Metab. 2002;  13 280-287
• 16 Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy.  Thyroid. 2007;  17 357-362
• 17 Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy.  Clin Endocrinol (Oxf). 1997;  47 9-14
• 18 Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nari M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx, Wiersinga WM. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.  EJE. 2008;  158 273-285
• 19 Dickinson JA, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy; use of a detailed protocol with comparative photographs for objective assessment.  Clin Endocrinol (Oxf). 2001;  55 283-303
• 20 European Group on Graves’ Orbitopathy (EUGOGO), . Wiersinga WM, Perros P, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Ordiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini M, Stahl M, von Arx G. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers.  Eur J Endocrinol. 2006;  155 387-389
• 21 Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy.  Endocrinol Metab Clin North Am. 1987;  16 391-407
• 22 Guidelines of the German Ophthalmologic Society about qualifying examination in road traffic. 2003;  , 3rd ed., 29
• 23 MacKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly G, Krassas G, Marcocci C, Marinò M, Mourits MP, Nardi M, Neoh C, Orgiazzi J, Perros P, Pinchera A, Pitz S, Prummel MF, Sartini MS, Wiersinga WM. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey.  Br J Ophthalmol. 2007;  91 455-458
• 24 Mourits MP, Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves’ orbitopathy: randomized placebo-controlled study.  Lancet. 2000;  355 1505-1509
• 25 Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Barolomei MP, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyreoidism and the course of Graves’ ophthalmopathy.  N Engl J Med. 1998;  338 73-78
• 26 Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ orbitopathy.  J Clin Endocrinol Metab. 2004;  89 15-20
• 27 Mourits MP, Kempen-Harteveldt ML, Garcia MB, Koppeschar HP, Tick L, Terwee CB. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study.  Lancet. 2000;  355 1505-1509
• 28 Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe eye disease.  Thyroid. 2000;  10 521
• 29 Marinò M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy.  Thyroid. 2004;  14 403-406

Correspondence